RxDoctor Payments Data

Tracye Zlobl, MD

Obstetrics & Gynecology · Naples, FLNPI 1801883939

Payments from drug & device makers

$2,810in general payments, 2019–2025

Across 148 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$775
  • Pfizer$331
  • Therapeuticsmd, Inc.$262
  • Myovant Sciences Inc.$227
  • Exeltis, USA Inc.$216
  • Mayne Pharma Commercial LLC$207
  • plus $793 from 18 others

What the payments were for

  • Food & beverage$2,69496%
  • Education$1164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,810 in reported general payments places this provider in the 75th percentile of 2,438 obstetrics & gynecology providers in Florida.

See all obstetrics & gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$135,160
Medicare patients
702
Services billed
6,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated42$13,204
Estradiol (Twice Weekly)Estradiol109$12,973
Estradiol170$10,014
ProgesteroneProgesterone, Micronized136$5,787
Climara ProEstradiol/Levonorgestrel12$4,874
DottiEstradiol17$3,126
ValacyclovirValacyclovir Hcl39$2,399
Estradiol (Once Weekly)Estradiol19$1,642
Raloxifene Hcl11$667
Clobetasol Propionate23$652
Levothyroxine Sodium44$409
Metronidazole12$401
Norethindrone Acetate16$312
Alprazolam25$195
Acyclovir16$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$331$13,20442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,438 obstetrics & gynecology providers in Florida.

Other obstetrics & gynecology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →